410 related articles for article (PubMed ID: 21224028)
1. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
Van Buren PN; Toto R
Adv Chronic Kidney Dis; 2011 Jan; 18(1):28-41. PubMed ID: 21224028
[TBL] [Abstract][Full Text] [Related]
2. Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy.
Wang Y; Wang C; Zhang X; Gu HF; Wu L
Curr Diabetes Rev; 2018; 14(2):149-161. PubMed ID: 28201968
[TBL] [Abstract][Full Text] [Related]
3. Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Sternlicht H; Bakris GL
Blood Purif; 2016; 41(1-3):139-43. PubMed ID: 26766168
[TBL] [Abstract][Full Text] [Related]
4. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
5. The role of angiotensin receptor blockers in diabetic nephropathy.
Sharma AM; Weir MR
Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
[TBL] [Abstract][Full Text] [Related]
6. PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease.
Fici F; Ari Bakir E; Ilkay Yüce E; Kanuncu S; Makel W; Tarim BA; Robles NR
High Blood Press Cardiovasc Prev; 2020 Feb; 27(1):43-49. PubMed ID: 31916208
[TBL] [Abstract][Full Text] [Related]
7. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
8. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
Mercier K; Smith H; Biederman J
Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
11. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Sarafidis PA; Ruilope LM
Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
[TBL] [Abstract][Full Text] [Related]
12. Current update in the management of diabetic nephropathy.
Van Buren PN; Toto R
Curr Diabetes Rev; 2013 Jan; 9(1):62-77. PubMed ID: 23167665
[TBL] [Abstract][Full Text] [Related]
13. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Eberhard R; Dikow R
Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
[TBL] [Abstract][Full Text] [Related]
15. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel AH; Karalliedde J; Mark PB; Patel DC; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
BMC Nephrol; 2022 Jan; 23(1):9. PubMed ID: 34979961
[TBL] [Abstract][Full Text] [Related]
16. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
de la Sierra A; Salazar J
Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
[TBL] [Abstract][Full Text] [Related]
17. Update on Diabetic Nephropathy: Core Curriculum 2018.
Umanath K; Lewis JB
Am J Kidney Dis; 2018 Jun; 71(6):884-895. PubMed ID: 29398179
[TBL] [Abstract][Full Text] [Related]
18. Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.
Toto RD
J Clin Hypertens (Greenwich); 2007 Nov; 9(11 Suppl 4):16-25. PubMed ID: 17978603
[TBL] [Abstract][Full Text] [Related]
19. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
20. Hypertension management in patients with diabetic nephropathy.
McCall AL
Curr Hypertens Rep; 2004 Aug; 6(4):272-9. PubMed ID: 15257861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
